(MENAFN- GlobeNewsWire - Nasdaq) Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030" report has been added to ResearchAndMarkets's offering.

Recombinant human fibroblast growth factors (rhFGF) are reshaping regenerative medicine and cosmetic therapeutics by enabling reliable, scalable biologic production. This market continues to accelerate as advanced expression platforms and process controls drive adoption across pharmaceutical and personal care sectors.

The recombinant human fibroblast growth factor market is experiencing robust expansion, propelled by scientific innovation and expanding applications in therapy and personal care. Bioengineered fibroblast growth factors underpin cutting-edge solutions across wound healing, tissue engineering, and research.

Strategic investments in both mammalian and microbial expression systems have enhanced production efficiency and protein activity consistency. Leaders in biotechnology and pharmaceuticals increasingly rely on these growth factors for new therapeutics and high-value formulations, while evolving regulatory frameworks accommodate emerging biologics standards. Increasing cross-sector collaborations and advanced purification techniques strengthen the global supply chain, supporting broader clinical and commercial integration.

Market Dynamics

• Increasing clinical approvals for recombinant human fibroblast growth factor therapies in chronic wound management
• Expansion of biosimilar production capacity driving cost competitiveness in fibroblast growth factor formulations
• Advancements in protein engineering enhancing stability and bioavailability of rhFGF for dermatological applications
• Strategic partnerships between biotech firms and contract manufacturers accelerating rhFGF market entry timelines
• Surge in demand for rhFGF-infused cosmetic products to address anti-aging and skin regeneration needs
• Growing research into combination therapies integrating rhFGF with stem cells for advanced tissue regeneration
• Adoption of continuous manufacturing technologies to improve rhFGF production efficiency and reduce supply bottlenecks
• Increasing investments in automated bioreactor systems to scale up rhFGF synthesis under GMP conditions

Key Takeaways & Competitive Insights

• Continued adoption of mammalian and yeast expression systems elevates purity and post-translational fidelity, supporting clinical and cosmetic use cases.
• Advancements in lyophilization and formulation science drive functional stability and enable distribution to global markets under varied storage conditions.
• Industry partnerships bridge R&D breakthroughs and commercial deployment, expediting translation of FGF variants into clinical studies and therapeutic formulations.
• Flexible manufacturing and digital monitoring approaches optimize yields and align with evolving quality standards.
• Strategic moves towards process intensification and cross-regional ventures mitigate supply chain disruptions and support efficient scaling.

Scope & Segmentation

Product Types: FGF-1 and FGF-2 for research pipelines and early-stage therapies; FGF-7, FGF-10, and FGF-21 targeting regenerative medicine and metabolic studies.

Applications:

• Anti-aging creams and hair growth serums in cosmetics.
• Research use in academic and industrial labs focusing on mechanistic evaluation and scale-up.
• Tissue engineering protocols for cell therapy and scaffolds.
• Wound healing in burns, diabetic ulcers, and surgical wound recovery.

End Users:

• Cosmetic product developers.
• Pharmaceutical companies, including biotech innovators and generic manufacturers.
• Research institutions advancing foundational science.

Formulation Types:

• Lyophilized powders for stable storage.
• Solutions offered in both single and multi-dose formats tailored for laboratory and clinical workflows.

Distribution Channels:

• E-commerce via direct-to-consumer platforms and third-party marketplaces.
• Hospital and retail pharmacies providing broad accessibility.

Regions:

• Americas with focus on the United States, Canada, Mexico, Brazil, and Argentina.
• Europe, Middle East, and Africa encompassing diverse markets such as United Kingdom, Germany, Saudi Arabia, South Africa, and more.
• Asia-Pacific, including China, India, Japan, Australia, and Southeast Asian markets.

Leading Companies:

• Thermo Fisher Scientific Inc.
• Bio-Techne Corporation
• Merck KGaA
• Lonza Group AG
• GenScript Biotech Corporation
• Sino Biological Inc.
• Creative Biolabs Co., Ltd.
• Abcam plc
• Proteintech Group, Inc.
• Novoprotein Scientific Inc.

Conclusion

The recombinant fibroblast growth factor market is defined by innovation, regulatory evolution, and resilient supply chains. Equipped with these insights, stakeholders can drive value creation, inform operational decisions, and shape the future trajectory of regenerative therapeutics and personal care advancements.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN14112025004107003653ID1110343701